

# Herantis Pharma to Host an R&D Update Webinar on October 26, 2021

Herantis Pharma Plc, Company release, 20 October 2021 at 9:30 EEST

**Herantis Pharma Plc (“Herantis or the Company”)**, focusing on disease modifying therapies for debilitating neurodegenerative diseases will October 26<sup>th</sup>, 2021 host an R&D Update Webinar. Herantis’ CEO Dr. Craig Cook and CSO Dr. Henri Huttunen will share progress in advancing Herantis’ HER-096 and rhCDNF programs.

## The R&D update will cover:

- Information about Herantis’ novel biomarker focused development program
- Data on efficient blood brain barrier (BBB) crossing
- Results from pre-clinical experiments showing potent neuroprotective effects
- Update on progress of its programs including non-invasive routes of administration

## Registration Details:

### Herantis Pharma's R&D Update Webinar

**Date:** Oct 26, 2021

**Time:** 11:00 EEST / 10:00 CEST

[Registered Here](#)

The webcast will also be available under “Company Live Presentations” in the Investors section of the Herantis’ website at [www.herantis.com/news-events/video-presentations/](http://www.herantis.com/news-events/video-presentations/). There will also have an opportunity to ask questions in a live Q&A session with speakers. A replay of the webcast will be archived on Herantis’ website following the presentation.

## For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [ir@herantis.com](mailto:ir@herantis.com)

**Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400**

**Company website:** [www.herantis.com](http://www.herantis.com)

## About the Speakers

### Dr. Craig Cook, MD, CEO of Herantis

Dr. Craig Cook, MD, is a medical doctor with an MBA from the London Business School and brings more than 20 years of experience in the international pharmaceutical and biotechnology sectors. Dr. Cook’s career has included increasingly senior roles in drug development and commercialization at major life science companies such as Eli Lilly, Johnson & Johnson, Novartis and EMD Serono, as well as entrepreneurial success in several healthcare initiatives. He was CEO of Midatech Pharma PLC, a dual Nasdaq and AIM listed biotech company, before deciding to join Herantis Pharma in 2020. He has worked across several therapeutic areas including neurology, immunology, and oncology.

### Dr. Henri Huttunen, CSO of Herantis

Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr.

Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. While he was an adjunct professor, Dr. Huttunen lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.

### **About Herantis Pharma Plc**

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson's Disease, Alzheimer's and other diseases. CDFN is a protein that occurs naturally in the body whose normal role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDFN – a biological protein – is Herantis' lead program and a clinical stage asset; and xCDFN (HER-096) – a synthetic peptide version of CDFN – is Herantis' follow-on program. Both CDFN and xCDFN (HER-096) have, via their multimodal mechanism of action, the potential improves neuronal survival and to stop the progression of Parkinson's and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit <https://www.herantis.com>